Ethnopharmacological landscape of Azadirachta indica (Neem): Phytochemical diversity bridging traditional heritage and modern medicine.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Azadirachta indica A. Juss. (neem) is a cornerstone of traditional medicine across tropical regions, recognized for its broad-spectrum therapeutic applications. However, the translation of its extensive ethnopharmacological legacy into evidence-based therapy is hindered by fragmented reports and a lack of systematic integration. AIM OF THE REVIEW: This narrative review aims to provide a quantitative and mechanistic synthesis of neem's phytochemical diversity and pharmacological landscape, explicitly distinguishing itself from prior work by mapping over 140 bioactive compounds to specific molecular pathways and clinical potential, while critically evaluating translational barriers. METHODS: A literature search of Web of Science, PubMed, and Scopus was conducted for peer-reviewed articles published between January 2001 and November 2025, using keywords related to Azadirachta indica, neem phytochemistry, pharmacology, and toxicology. RESULTS: Phytochemical investigations have identified over 140 distinct compounds, including limonoids (e.g., azadirachtin, nimbolide, gedunin), flavonoids, and phenolic acids, distributed across all plant parts. These compounds modulate core signaling hubs-NF-κB, PI3K/Akt/mTOR, Nrf2, and MAPK-underpinning a broad pharmacological spectrum. Preclinical studies suggest that neem-derived compounds exhibit antiproliferative activity against breast, cervical, colon, and prostate cancer cell lines, although in vitro IC50 values alone are not predictive of clinical efficacy. Neem extracts and phytochemicals have also demonstrated neuroprotective effects in experimental models of Alzheimer's and Parkinson's diseases and antidiabetic activity in streptozotocin-induced diabetic rodents; however, the translational relevance of these findings to human disease remains to be established through rigorous clinical investigation. Beyond human health, neem's insecticidal and antifeedant properties support eco-friendly agricultural applications. However, clinical validation remains strikingly limited: only fifteen interventional trials are registered, most for oro-dental conditions, with no published phase II/III results for systemic diseases. Toxicological reports confirm dose- and route-dependent risks, including pediatric encephalopathy from neem oil ingestion and embryotoxicity, necessitating explicit safety guidelines. CONCLUSIONS: Neem possesses validated, multi-target therapeutic potential, yet its clinical translation is currently impeded by poor bioavailability, extract standardization gaps, and a paucity of rigorous human trials. Future research must prioritize pharmacokinetic optimization (e.g., nanoformulations), establishment of certified reference materials, and well-designed phase trials in oncology and metabolic disease, rather than further preclinical cataloging.